Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR Eye Drops vs. Xalatan® Eye Drops for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma
ISRCTN | ISRCTN80385690 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN80385690 |
EudraCT/CTIS number | 2008-002122-10 |
Secondary identifying numbers | RDR 342; EudrCT-Number: 2008-002122-10 |
- Submission date
- 29/10/2010
- Registration date
- 01/11/2010
- Last edited
- 11/08/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Not provided at time of registration
Contact information
Dr Gunther Kahle
Scientific
Scientific
Kurfürstendamm Nr 69
Berlin
10707
Germany
Study information
Study design | Prospective multicentre two arm randomised investigator blind parallel group clinical trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use contact details below to request a patient information sheet |
Scientific title | Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma with Xalatan® 0.005% Eye Drops: A multicenter, randomized, investigator-blind clinical trial with parallel groups |
Study acronym | RDR 342 |
Study hypothesis | The study drug is tested for non-inferiority in comparison to Xalatan® |
Ethics approval(s) | The Ethics Committee of the State of Berlin, State Office of Health and Welfare (Ethik-Kommission des Landes Berlin, Landesamt für Gesundheit und Soziales [LAGeSo]) approved on the 17th of October 2008 (ref: ZS EK 14 280/08) |
Condition | Ocular Hypertension; Primary Open Angle Glaucoma |
Intervention | Test Drug: Latanoprost 0.005% RDR Eye Drops Reference Drug: Xalatan® 0.005% Eye Drops Patients are randomised to receive either the test drug or the reference drug. Dose, duration, frequency and mode of application is the same for both: Dose: 1 drop Duration: 42 days Frequency: once a day Mode of application: The drug is to be dropped into the affected eye(s) Possible Interim Drugs (for patients treated with prostaglandins or betablockers at baseline, undergoing a 4 week washout period) Dorzolamide-containing eye-drops (20 mg/ml), or Pilocarpine-containing eye-drops (20 mg/ml) The interim drug may be described by the Investigator for a period of three weeks. The interim drug should be stopped one week or 3 days, respectively, before the baseline investigation and start of study medication. For either medication: Dose: 1 drop Frequency: 3 times a day Duration of the study is up to 10 weeks for subjects (6 weeks treatment, + 4 weeks wash out phase only if necessary), with 4 visits including initial screening/consenting visit. |
Intervention type | Other |
Primary outcome measure | Intra-ocular pressure: Mean change of the 8 am IOP from baseline value to end of study value measured on the study eye |
Secondary outcome measures | 1. Efficacy 1.1. Mean change of the 8am IOP from baseline value to visit 2 1.2. Mean change of the 12noon and 4pm IOP from baseline value to visit 2 and to end of study value 2. Safety 2.1. Adverse Events 2.2. Subjective tolerance 2.3. Ophthalmologic examinations 2.4. Vital signs |
Overall study start date | 25/05/2009 |
Overall study end date | 10/12/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 260 |
Participant inclusion criteria | 1. Unilateral or bilateral ocular hypertension or primary open angle glaucoma at an early stage 2. In at least one eye, IOP ≥ 22 mmHg at 8am and IOP ≤ 30 mmHg at 8 am, 12 noon and 4 pm under the following conditions: 2.1. untreated ocular hypertension, or 2.2. 4 week washout period of an initial monotherapy with a prostaglandin or beta-blocker 3. Best corrected visual acuity ≥ 20/100 (Snellen) or 2/10 (Monoyer) 4. Male and female patients, age ≥ 18 years 5. Female subjects of childbearing age must be using a medically accepted form of birth control and must have a negative urine pregnancy test at screening 6. Able to provide informed consent after risks and benefits of the study have been explained 7. Ability to communicate effectively with study personnel 8. Written informed consent |
Participant exclusion criteria | 1. In both eyes, IOP < 22 mmHg 2. IOP > 30 mmHg 3. Known sensitivity to latanoprost or any component of the drug products 4. Use of contact lenses 5. Other defined ocular diseases, ocular interventions, or ocular medications 6. Pregnancy or breastfeeding 7. Other defined diseases such as dysfunction of the liver or the kidneys, cancer, angina pectoris, asthma bronchiale, haematological diseases 8. Current or anamnestic drug addiction or extensive alcohol use 9. Participation in another clinical study within 4 weeks prior to enrolment 10. History of non-compliance 11. Any condition that compromises the ability to understand or comply with study requirements 12. Committed to an institution by virtue of an order issued either by the judicial or the administrative authorities |
Recruitment start date | 25/05/2009 |
Recruitment end date | 10/12/2009 |
Locations
Countries of recruitment
- Bulgaria
- Germany
- Latvia
- Poland
Study participating centre
Kurfürstendamm Nr 69
Berlin
10707
Germany
10707
Germany
Sponsor information
RDR Pharma GmbH (Germany)
Industry
Industry
Frohmestraße 78d
Hamburg
22459
Germany
Funders
Funder type
Industry
Bausch & Lomb GmbH (Germany)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |